SERA (Sera Prognostics, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SERA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Zhenya Lindgardt | Chief Executive Officer | Sell | — | — |
| 2026-09-01 | Scott Gleason | Chief Financial Officer | A | — | — |
| 2026-07-14 | Mansoor Raza Mirza | Director | A | — | — |
| 2026-07-14 | Jane F Barlow | Director | A | — | — |
| 2026-07-14 | GREGORY C CRITCHFIELD | Director | A | — | — |
| 2026-07-14 | Joshua Phillips | Director | A | — | — |
| 2026-07-14 | Sandra AJ Lawrence | Director | A | — | — |
| 2026-07-14 | Kim P. Kamdar | Director | A | — | — |
| 2026-07-14 | Mark Christopher Capone | Director | A | — | — |
| 2026-06-15 | Zhenya Lindgardt | Chief Executive Officer | Sell | — | — |
| 2026-06-15 | Benjamin Jackson | General Counsel | Sell | — | — |
| 2026-06-15 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | Sell | — | — |
| 2026-06-15 | Austin Aerts | Chief Financial Officer | Sell | — | — |
| 2026-06-15 | Tiffany Eul Davis Inglis | Chief Medical Officer | Sell | — | — |
| 2026-06-10 | Austin Aerts | Chief Financial Officer | Sell | — | — |
| 2026-06-10 | Zhenya Lindgardt | Chief Executive Officer | Sell | — | — |
| 2026-06-09 | Sandra AJ Lawrence | Director | Sell | — | — |
| 2026-06-01 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | A | — | — |
| 2026-06-01 | Benjamin Jackson | General Counsel | A | — | — |
| 2026-03-13 | Zhenya Lindgardt | Chief Executive Officer | A | — | — |
| 2026-03-13 | Tiffany Eul Davis Inglis | Chief Medical Officer | A | — | — |
| 2026-03-13 | Austin Aerts | Chief Financial Officer | A | — | — |
| 2026-03-13 | Benjamin Jackson | General Counsel | A | — | — |
| 2026-03-13 | Dyaarl Lee Anderson Jr. | Chief Commercial Officer | A | — | — |
| 2026-03-12 | Robert Gardner Harrison | Chief Information Officer | Sell | — | — |
| 2026-03-12 | Benjamin Jackson | General Counsel | Sell | — | — |
| 2026-03-12 | John J. Boniface | Chief Scientific Officer | Sell | — | — |
| 2026-03-12 | Paul Kearney | Chief Data Officer | Sell | — | — |
| 2026-03-12 | Austin Aerts | Chief Financial Officer | Sell | — | — |
| 2026-03-12 | Zhenya Lindgardt | Chief Executive Officer | Sell | — | — |
| 2026-03-10 | Austin Aerts | Chief Financial Officer | Sell | — | — |
| 2026-03-10 | Benjamin Jackson | General Counsel | Sell | — | — |
| 2026-03-10 | Paul Kearney | Chief Data Officer | Sell | — | — |
| 2026-03-10 | Robert Gardner Harrison | Chief Information Officer | Sell | — | — |
| 2026-03-10 | John J. Boniface | Chief Scientific Officer | Sell | — | — |
| 2026-03-06 | Sandra AJ Lawrence | Director | Sell | — | — |
| 2026-02-24 | Robert Gardner Harrison | Chief Information Officer | Sell | — | — |
| 2026-02-04 | Kim P. Kamdar | Director | J | — | — |
| 2026-01-27 | Robert Gardner Harrison | Chief Information Officer | Sell | — | — |
| 2025-12-30 | Robert Gardner Harrison | Chief Information Officer | Sell | — | — |
| 2025-12-11 | Austin Aerts | Chief Financial Officer | Sell | — | — |
| 2025-12-11 | John J. Boniface | Chief Scientific Officer | Sell | — | — |
| 2025-12-11 | Zhenya Lindgardt | Chief Executive Officer | Sell | — | — |
| 2025-12-11 | Robert Gardner Harrison | Chief Information Officer | Sell | — | — |
| 2025-12-11 | Benjamin Jackson | General Counsel | Sell | — | — |
| 2025-12-11 | Paul Kearney | Chief Data Officer | Sell | — | — |
| 2025-12-10 | Zhenya Lindgardt | Chief Executive Officer | Sell | — | — |
| 2025-12-10 | Austin Aerts | Chief Financial Officer | Sell | — | — |
| 2025-12-08 | Sandra AJ Lawrence | Director | Sell | — | — |
| 2025-12-05 | Mansoor Raza Mirza | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,515,595 | — |
| — | Chief Executive Officer | 845,292 | — |
| — | Chief Executive Officer | 844,870 | — |
| — | Chief Financial Officer | 301,190 | — |
| — | Chief Data Officer | 163,961 | — |
| — | General Counsel | 161,756 | — |
| — | Chief Scientific Officer | 145,842 | — |
| — | Chief Financial Officer | 117,924 | — |
| — | Chief Medical Officer | 92,075 | — |
| — | Director | 86,505 | — |
| — | Director | 80,166 | — |
| — | Chief Commercial Officer | 77,998 | — |
| — | 10%+ Owner | 77,420 | — |
| — | Chief Information Officer | 76,712 | — |
| — | Director | 74,557 | — |
| — | Director | 54,999 | — |
| — | Director | 47,088 | — |
| — | Director | 44,379 | — |
| — | Director | 38,899 | — |
| — | Chief Financial Officer | 35,630 | — |
| — | Director | 30,534 | — |
| — | Chief Medical Officer | 27,000 | — |
| — | Chief Commercial Officer | 18,300 | — |
| — | Director | 7,117 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SERA quote page; the site-wide leaderboard is on the insider transactions hub.